The content on this site is intended for healthcare professionals only
In 1999 Roger Wilson was diagnosed with an extremely rare form of soft tissue sarcoma. Roger discusses the difficulties encountered patients suffering from such rare diseases and explains how in 2003 he and his wife Sheelagh formed Sarcoma UK. Sarcoma UK was established as an information and support organisation for patients with these rare cancers and by 2007 was working with 600 other patients and national organisations such as NICE, the National Cancer Action Team, Macmillan Cancer Support and the National Cancer Research Institute. In March 2011 Sarcoma UK became a registered charity and now has a small full time staff, a growing research programme funding scientific and medical research and a group of volunteers running local support groups and on-line support resources.
Denikitug shows immune activation and early anti-tumour activity in advanced solid tumour
Zedoresertib plus lunresertib shows promising tumour shrinkage in CCNE1-amplified and FBXW7-mutant cancers
Dual integrin inhibitor plus pembrolizumab shows durable responses in ICI-resistant solid tumours
Oral molecular glue degrader with or without spartalizumab shows immune activation and tumour control in solid tumours
ZL-1310 shows promising activity in DLL3-positive neuroendocrine carcinomas
Dose escalation of RG6344 demonstrates safety and promising activity in BRAF V600E solid tumours
WRN inhibitor shows promise in patients with MSI and/or dMMR advanced solid tumours
Daratumumab, bortezomib/thalidomide/dexamethasone (D-VTd) and DARA maintenance shows benefit in transplant-eligible NDMM
Made to measure: Choosing the optimal regimen in transplant-eligible NDMM
